作者: David A Reardon , Gamal Akabani , R Edward Coleman , Allan H Friedman , Henry S Friedman
关键词: Anaplastic astrocytoma 、 Chemotherapy 、 Surgically-Created Resection Cavity 、 Pathology 、 Gastroenterology 、 Medicine 、 Survival rate 、 Glioma 、 Internal medicine 、 Central nervous system disease 、 Radiation therapy 、 Toxicity
摘要: PURPOSE: To assess the efficacy and toxicity of intraresection cavity 131I-labeled murine antitenascin monoclonal antibody 81C6 determine its true response rate among patients with newly diagnosed malignant glioma. PATIENTS AND METHODS: In this phase II trial, 120 mCi was injected directly into surgically created resection 33 previously untreated glioma (glioblastoma multiforme [GBM], n = 27; anaplastic astrocytoma, 4; oligodendroglioma, 2). Patients then received conventional external-beam radiotherapy followed by a year alkylator-based chemotherapy. RESULTS: Median survival for all those GBM 86.7 79.4 weeks, respectively. Eleven remain alive at median follow-up 93 weeks (range, 49 to 220 weeks). Nine (27%) developed reversible hematologic toxicity, histologically confirmed, treatment-related neurologic occurred in five (15%). One patient (3%) ...